New type of prosthesis combined with rhBMP-2 delivery system
New type of prosthesis combined with rhBMP-2 delivery system
批准号:
12671403
负责人:
SAITO Naoto
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
尽管存在机械松动和不可避免的翻修手术的潜在风险,但全髋关节置换术被广泛接受用于重建受损髋关节。在此类翻修手术中,我们经常在股骨近端或髋臼遇到不同程度的假体周围骨缺损,即使使用自体或异体植骨和各种生物材料,也很难获得稳定的新髋关节假体位置。为了解决这一问题,我们设计了一种新的方法,利用DNA重组产生的人型生长因子骨形态发生蛋白-2 (rhBMP-2)结合一种新的合成可生物降解聚合物(PLA-DX-PEG)作为rhBMP-2递送的载体材料来修复骨缺损。在本报告中,我们介绍了rhBMP-2保留假体重建犬骨缺损模型的疗效。在该模型中,手术切除股骨头和股骨近端内侧半段,使骨缺损得到修复。以rhBMP-2 (100 μ、500 μ g或1000 μ g)/PLA-DX-PEG(100mg)复合材料浸渍制备部分多孔结构的假体。在对照动物中,将不含rhBMP-2的PLA-DX-PEG聚合物填充到多孔表面。术后2周、4周、8周和12周通过常规x线摄影检查近端骨缺损处的新骨形成情况。100、500μ g和1000 μ g rhBMP-2组(n=4)在4周内沿骨缺损出现明确的透影,透影区大小与rhBMP-2剂量有关。术后8周,不透光阴影更加明显。在对照组动物中,在实验期间骨缺损处未发现不透射线阴影。术后12周,处死动物,取近端股骨。肉眼组织学和影像学检查显示,500和1000 m μ g rhBMP-2组原骨缺损完全修复,假体在股骨近端固定良好。在100 μ g组,缺损部分以薄的新骨修复。在对照组中,缺损不修复,由纤维组织覆盖。光镜检查显示,12周后新生骨被重塑为板层骨。综上所述,这种假体联合rhBMP-2传递系统可能为我们提供一种新的方式来修复翻修关节成形术中遇到的骨缺损或骨量丢失,而不需要植骨。少
英文摘要
Total hip arthroplasty is widely accepted for reconstruction of damaged hip joints in spite of potential risk for mechanical loosening and inevitable revision surgery. In such revision surgeries, we often encounter peri-prosthetic bone defects of various grades either in proximal femur or in acetabulum, which often make difficult to obtain stable setting of a new hip prosthesis even if with use of auto- or allogenous bone grafting and various biomaterials. In order to address this problem, we devised new method to repair the bone defect with use of a growth factor bone morphogenetic protein-2 of human type, produced by DNA recombination ( rhBMP-2) in combination with a new synthetic biodegradable Polymer( PLA-DX-PEG ) as a carrier material for the rhBMP-2 delivery. In this report we present the efficacy of the rhBMP-2 retaining prosthesis to reconstruct bone defect in a canine model. In this model, femoral head and medial halfofthe proximal femur was surgically resected to make the bon … More e defect to be repaired. And the prosthesis with partially porous structured Surface which was impregnated with rhBMP-2 ( 100 μ, 500 μ g or 1000 μ g )/PLA-DX-PEG( 100mg ) composite. In control animals, PLA-DX-PEG polymer without rhBMP-2 was packed into the porous surface. New bone formation at the proximal bone defects was examined by routine radiography at 2, 4, 8 and 12 weeks after surgery. In 100, 500μ g and 1,000 μ g rhBMP-2 groups ( n=4 respectively ) definite radiopaque shadows appeared along the bone defects in 4 week and the sizes of the radiopaque area were depended on the rhBMP-2 doses. The radiopaque shadows became more obvious at 8 weeks alter surgery. In control animals, no radiopaque shadow was noted at the bone defect over the experimental period of time. At 12 weeks after surgery, the animals were sacrificed and proximal femurs were harvested. On macroscopic histology and radiology, original bone defects in 500 and 1,000m μ g rhBMP-2 groups were completely repaired and thef prostheses were well fixed within the proximal femurs. In 100 μ g group, the defects were partially repaired with thin new bone. In controls, the defects were left un-repaired and covered by fibrous tissue. On light microscopic examination, the newly formed bone was remodeled to lamellar bone in 12 weeks. In summary, this type of prosthesis combined with rhBMP-2 delivery system might provide us a new modality to restore bone defect or lost bone mass encountered in revision arthroplasty without bone grafting. Less
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Murakami N, Saito N, et al.: "Effect of phosphodiesterase inhibitor 4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2"Bone. (in press).
Murakami N、Saito N 等人:“磷酸二酯酶抑制剂 4 咯利普兰对重组人骨形态发生蛋白 2 形成新骨的影响”骨。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kinoshita T,Kobayashi S, et al.: "Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice."Bone. 27. 811-817 (2000)
Kinoshita T、Kobayashi S 等人:“磷酸二酯酶抑制剂己酮可可碱和咯利普兰主要通过促进正常小鼠的骨形成来增加骨量。”骨。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Horiuchi H,Saito N, et al.: "Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline."Bone. (in press).
Horiuchi H、Saito N 等人:“通过磷酸二酯酶抑制剂己酮可可碱增强小鼠骨形态发生蛋白 2 诱导的新骨形成。”骨。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kobayashi S, Saito N, et al.: "Poor bone quality or hip structure as risk factors affecting survival of total-hip arthroplasty"Lancet. 355. 1499-1504 (2000)
Kobayashi S、Saito N 等人:“骨质量或髋部结构不良是影响全髋关节置换术存活的危险因素”《柳叶刀》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Horiuchi,H., Saito,N., et al: "Effect of phosphodiesterase inhibitor 4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2"Bone. in press.
Horiuchi,H.、Saito,N. 等人:“磷酸二酯酶抑制剂 4 咯利普兰对重组人骨形态发生蛋白 2 形成新骨的影响”Bone。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 16 条
Development of a biofunctional scaffold using nanocarbon fiber sheets for bone regenaration
-
批准号:24659670
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2012
-
负责人:SAITO Naoto
-
依托单位:
Establishment and safety evaluation of carbon nanotube (CNT) bio-interface technology for developing high-function biomaterials using CNTs
-
批准号:24241045
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$30.37万
-
财政年份:2012
-
负责人:SAITO Naoto
-
依托单位:
Development of carbon nanotube/ceramic composites as new biomaterials for artificial joint
-
批准号:18201021
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$33.03万
-
财政年份:2006
-
负责人:SAITO Naoto
-
依托单位:
Development of new prostheses for arthroplasty with an added ability to promote bone repair using bone morphogenetic protein (BMP)
-
批准号:14370459
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.77万
-
财政年份:2002
-
负责人:SAITO Naoto
-
依托单位:
Synthetic biodegradable polymers as injectable delivery systems for BMPs
-
批准号:10671351
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:1998
-
负责人:SAITO Naoto
-
依托单位:
国内基金
海外基金
基于"Carrier-free"概念构建的高载药量的主动靶向双药纳米纤维递药体系的疗效评价及机制研究
-
批准号:81472781
-
项目类别:面上项目
-
资助金额:74.0万元
-
批准年份:2014
-
负责人:李晓林
-
依托单位: